Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms

References

• Abbara A, Chitty S, Roe JK, Ghani R, Collin SM, Ritchie A, Kon OM, Dzvova J, Davidson H, Edwards TE, et al. 2017. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis. 17(1):231.
   PubMed Web of Science ®Google Scholar
• Acharya SK. 2021. Acute liver failure: Indian perspective. Clin Liver Dis. 18(3):143–149.
   Google Scholar
• Ali AAM, Abdel-Ghaffar O, Aly DAM. 2022. The protective effect of naringenin against pyrazinamide-induced hepatotoxicity in male Wistar rats. JOBAZ. 83(1):49.
   Google Scholar
• Attri S, Rana SV, Vaiphei K, Sodhi CP, Katyal R, Goel RC, Nain CK, Singh K. 2000. Isoniazid and rifampicin-induced oxidative hepatic injury-protection by N-acetylcysteine. Hum Exp Toxicol. 19(9):517–522.
   PubMed Web of Science ®Google Scholar
• Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. 2011. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 54(4):773–794.
   PubMed Web of Science ®Google Scholar
• Bénichou C. 1990. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 11:272–276.
   PubMed Web of Science ®Google Scholar
• Bhilare NV, Dhaneshwar SS, Mahadik KR, Dasgupta A. 2022. Co-drug of isoniazid and sulfur containing antioxidant for attenuation of hepatotoxicity and treatment of tuberculosis. Drug Chem Toxicol. 45(2):850–860.
   PubMed Web of Science ®Google Scholar
• Biswas A, Santra S, Bishnu D, Dhali GK, Chowdhury A, Santra A. 2020. Isoniazid and rifampicin produce hepatic fibrosis through an oxidative stress-dependent mechanism. Int J Hepatol. 2020:6987295.
   PubMed Web of Science ®Google Scholar
• Björnsson ES. 2020. Epidemiology, predisposing factors, and outcomes of drug-induced liver injury. Clin Liver Dis. 24(1):1–10.
   PubMed Web of Science ®Google Scholar
• Björnsson HK, Björnsson ES. 2022. Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 97:26–31.
   PubMed Web of Science ®Google Scholar
• Chamorro JG, Castagnino JP, Musella RM, Nogueras M, Aranda FM, Frías A, Visca M, Aidar O, Perés S, de Larrañaga GF. 2013. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol. 28(2):323–328.
   PubMed Web of Science ®Google Scholar
• Chen J, Raymond K. 2006. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 5:3.
   PubMedGoogle Scholar
• Chen X, Xu J, Zhang C, Yu T, Wang H, Zhao M, Duan ZH, Zhang Y, Xu JM, Xu DX. 2011. The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice. Eur J Pharmacol. 659(1):53–60.
   PubMed Web of Science ®Google Scholar
• Cheng J, Krausz KW, Li F, Ma X, Gonzalez FJ. 2013. CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid. Toxicol Appl Pharmacol. 266(2):245–253.
   Google Scholar
• Chou C, Veracruz N, Chitnis AS, Wong RJ. 2022. Risk of drug-induced liver injury in chronic hepatitis B and tuberculosis co-infection: a systematic review and meta-analysis. J Viral Hepat. 29(12):1107–1114.
   PubMed Web of Science ®Google Scholar
• Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK. 2006. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol. 45(1):117–126.
   PubMed Web of Science ®Google Scholar
• Dartois VA, Rubin EJ. 2022. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 20(11):685–701.
   PubMed Web of Science ®Google Scholar
• Dash A, Figler RA, Sanyal AJ, Wamhoff BR. 2017. Drug-induced steatohepatitis. Expert Opin Drug Metab Toxicol. 13(2):193–204.
   PubMed Web of Science ®Google Scholar
• Debre R, Perdrizet S, Lotte A, Naveau M, Lert F. 1973. Isoniazid chemoprophylaxis of latent primary tuberculosis: in five trial centres in France from 1959 to 1969. Int J Epidemiol. 2(2):153–160.
   PubMed Web of Science ®Google Scholar
• Devaraj E, Perumal E, Subramaniyan R, Mustapha N. 2022. Liver fibrosis: extracellular vesicles mediated intercellular communication in perisinusoidal space. Hepatology. 76(1):275–285.
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Patil M, Reddy VV, Singh R, Joseph T, Ganga D. 2018. Drug-induced acute liver failure in children and adults: results of a single-centre study of 128 patients. Liver Int. 38(7):1322–1329.
   PubMed Web of Science ®Google Scholar
• Devarbhavi H, Singh R, Patil M, Sheth K, Adarsh CK, Balaraju G. 2013. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol. 28(1):161–167.
   PubMed Web of Science ®Google Scholar
• Donato MT, Jiménez N, Serralta A, Mir J, Castell JV, Gómez-Lechón MJ. 2007. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol in Vitro. 21(2):271–276.
   PubMed Web of Science ®Google Scholar
• Edwards BD, Mah H, Sabur NF, Brode SK. 2023. Hepatotoxicity and tuberculosis treatment outcomes in chronic liver disease. J Assoc Med Microbiol Infect Dis Can. 8(1):64–74.
   PubMedGoogle Scholar
• Enriquez-Cortina C, Almonte-Becerril M, Clavijo-Cornejo D, Palestino-Domínguez M, Bello-Monroy O, Nuño N, López A, Bucio L, Souza V, Hernández-Pando R, et al. 2013. Hepatocyte growth factor protects against isoniazid/rifampicin-induced oxidative liver damage. Toxicol Sci. 135(1):26–36.
   PubMed Web of Science ®Google Scholar
• Erwin ER, Addison AP, John SF, Olaleye OA, Rosell RC. 2019. Pharmacokinetics of isoniazid: the good, the bad, and the alternatives. Tuberculosis. 116S:S66–S70.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. 2019. Electronic address: [email protected]; Clinical practice guideline panel: chair: panel members; EASL governing board representative: EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 70(6):1222–1261.
   PubMed Web of Science ®Google Scholar
• Ezhilarasan D, Evraerts J, Brice S, Buc-Calderon P, Karthikeyan S, Sokal E, Najimi M. 2016. Silibinin inhibits proliferation and migration of human hepatic stellate LX-2 Cells. J Clin Exp Hepatol. 6(3):167–174.
   PubMedGoogle Scholar
• Ezhilarasan D, Raghunandhakumar S. 2021. Boldine treatment protects acetaminophen-induced liver inflammation and acute hepatic necrosis in mice. J Biochem Mol Toxicol. 35(4):e22697.
   PubMed Web of Science ®Google Scholar
• Ezhilarasan D. 2021a. Dapsone-induced hepatic complications: it’s time to think beyond methemoglobinemia. Drug Chem Toxicol. 44(3):330–333.
   PubMed Web of Science ®Google Scholar
• Ezhilarasan D. 2021b. Hepatotoxic potentials of methotrexate: understanding the possible toxicological molecular mechanisms. Toxicology. 458:152840.
   PubMed Web of Science ®Google Scholar
• Ezhilarasan D, Sokal E, Najimi M. 2018. Hepatic fibrosis: it is time to go with hepatic stellate cell-specific therapeutic targets. Hepatobiliary Pancreat Dis Int. 17(3):192–197.
   PubMed Web of Science ®Google Scholar
• Fountain FF, Tolley E, Chrisman CR, Self TH. 2005. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest. 128(1):116–123.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2001. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection–New York and Georgia, 2000. JAMA. 285(20):2572–2573.
   PubMed Web of Science ®Google Scholar
• Guo HL, Hassan HM, Ding PP, Wang SJ, Chen X, Wang T, Sun LX, Zhang LY, Jiang ZZ. 2017. Pyrazinamide-induced hepatotoxicity is alleviated by 4-PBA via inhibition of the PERK-eIF2α-ATF4-CHOP pathway. Toxicology. 378:65–75.
   PubMed Web of Science ®Google Scholar
• Guo HL, Hassan HM, Zhang Y, Dong SZ, Ding PP, Wang T, Sun LX, Zhang LY, Jiang ZZ. 2016. Pyrazinamide induced rat cholestatic liver injury through inhibition of FXR regulatory effect on bile acid synthesis and transport. Toxicol Sci. 152(2):417–428.
   PubMed Web of Science ®Google Scholar
• Halilbasic E, Claudel T, Trauner M. 2013. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol. 58(1):155–168.
   PubMed Web of Science ®Google Scholar
• Hassan HM, Guo HL, Yousef BA, Luyong Z, Zhenzhou J. 2015. Hepatotoxicity mechanisms of isoniazid: a mini-review. J Appl Toxicol. 35(12):1427–1432.
   PubMed Web of Science ®Google Scholar
• He F, Ru X, Wen T. 2020. NRF2, a transcription factor for stress response and beyond. IJMS. 21(13):4777.
   Web of Science ®Google Scholar
• He X, Song Y, Wang L, Xu J. 2020. Protective effect of pyrrolidine dithiocarbamate on isoniazid/rifampicin‑induced liver injury in rats. Mol Med Rep. 21(1):463–469.
   PubMed Web of Science ®Google Scholar
• Holdiness MR. 1984. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet. 9(6):511–544.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Björnsson ES. 2019. Drug-induced liver injury–types and phenotypes. N Engl J Med. 381(3):264–273.
   PubMed Web of Science ®Google Scholar
• Huang JH, Zhang C, Zhang DG, Li L, Chen X, Xu DX. 2016. Rifampicin-induced hepatic lipid accumulation: association with up-regulation of peroxisome proliferator-activated receptor γ in mouse liver. PLOS One. 11(11):e0165787.
   PubMed Web of Science ®Google Scholar
• Hussain Z, Zhu J, Ma X. 2021. Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug. Drug Metab Dispos. 49(8):679–682.
   PubMed Web of Science ®Google Scholar
• Ichai P, Saliba F, Antoun F, Azoulay D, Sebagh M, Antonini TM, Escaut L, Delvart V, Castaing D, Samuel D. 2010. Acute liver failure due to antitubercular therapy: strategy for antitubercular treatment before and after liver transplantation. Liver Transpl. 16(10):1136–1146.
   PubMed Web of Science ®Google Scholar
• Iorga A, Dara L, Kaplowitz N. 2017. Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. IJMS. 18(5):1018.
   Web of Science ®Google Scholar
• Jaramillo-Valverde L, Levano KS, Tarazona DD, Capristano S, Zegarra-Chapoñan R, Sanchez C, Yufra-Picardo VM, Tarazona-Santos E, Ugarte-Gil C, Guio H. 2022. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients. Mol Genet Genomic Med. 10(8):e1987.
   PubMed Web of Science ®Google Scholar
• Jia ZL, Cen J, Wang JB, Zhang F, Xia Q, Wang X, Chen XQ, Wang RC, Hsiao CD, Liu KC, et al. 2019. Mechanism of isoniazid-induced hepatotoxicity in zebrafish larvae: activation of ROS-mediated ERS, apoptosis and the Nrf2 pathway. Chemosphere. 227:541–550.
   PubMed Web of Science ®Google Scholar
• Kabbara WK, Sarkis AT, Saroufim PG. 2016. Acute and fatal isoniazid-induced hepatotoxicity: a case report and review of the literature. Case Rep Infect Dis. 2016:3617408.
   PubMedGoogle Scholar
• Karthikeyan S. 2005. Isoniazid and rifampicin treatment on phospholipids and their subfractions in liver tissue of rabbits. Drug Chem Toxicol. 28(3):273–280.
   PubMed Web of Science ®Google Scholar
• Kim JH, Nam WS, Kim SJ, Kwon OK, Seung EJ, Jo JJ, Shresha R, Lee TH, Jeon TW, Ki SH, et al. 2017. Mechanism investigation of rifampicin-induced liver injury using comparative toxicoproteomics in mice. IJMS. 18(7):1417.
   Web of Science ®Google Scholar
• Kolarić TO, Ninčević V, Smolić R, Smolić M, Wu GY. 2019. Mechanisms of hepatic cholestatic drug injury. J Clin Transl Hepatol. 7(1):86–92.
   PubMed Web of Science ®Google Scholar
• Korver S, Bowen J, Pearson K, Gonzalez RJ, French N, Park K, Jenkins R, Goldring C. 2021. The application of cytokeratin-18 as a biomarker for drug-induced liver injury. Arch Toxicol. 95(11):3435–3448.
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Andrade RJ, Merz M, End P, Benesic A, Gerbes AL, Aithal GP. 2017. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 66(6):1154–1164.
   PubMed Web of Science ®Google Scholar
• Lee YK, Park JE, Lee M, Hardwick JP. 2018. Hepatic lipid homeostasis by peroxisome proliferator-activated receptor gamma 2. Liver Res. 2(4):209–215.
   PubMedGoogle Scholar
• Lei S, Gu R, Ma X. 2021. Clinical perspectives of isoniazid-induced liver injury. Liver Res. 5(2):45–52.
   Google Scholar
• Li X, Tang J, Mao Y. 2022. Incidence and risk factors of drug-induced liver injury. Liver Int. 42(9):1999–2014.
   PubMed Web of Science ®Google Scholar
• Lian Y, Zhao J, Xu P, Wang Y, Zhao J, Jia L, Fu Z, Jing L, Liu G, Peng S. 2013. Protective effects of metallothionein on isoniazid and rifampicin-induced hepatotoxicity in mice. PLOS One. 8(8):e72058.
   PubMed Web of Science ®Google Scholar
• Libby AE, Bales E, Orlicky DJ, McManaman JL. 2016. Perilipin-2 deletion impairs hepatic lipid accumulation by interfering with sterol regulatory element-binding protein (SREBP) activation and altering the hepatic lipidome. J Biol Chem. 291(46):24231–24246.
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang L, Joo D, Sun SC. 2017. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2:17023–17023.
   PubMed Web of Science ®Google Scholar
• Masuka JT, Chipangura P, Nyambayo PP, Stergachis A, Khoza S. 2018. A comparison of adverse drug reaction profiles in patients on antiretroviral and antitubercular treatment in zimbabwe. Clin Drug Investig. 38(1):9–17.
   PubMed Web of Science ®Google Scholar
• McAtee C. 2022. Drug-induced liver injury. Crit Care Nurs Clin North Am. 34(3):267–275.
   PubMed Web of Science ®Google Scholar
• McGill MR, Jaeschke H. 2019. Biomarkers of drug-induced liver injury. Adv Pharmacol. 85:221–239.
   PubMedGoogle Scholar
• Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, et al. 2018. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 379(5):440–453.
   PubMed Web of Science ®Google Scholar
• Metushi I, Uetrecht J, Phillips E. 2016. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol. 81(6):1030–1036.
   PubMed Web of Science ®Google Scholar
• Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD. 1976. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 84(2):181–192.
   PubMed Web of Science ®Google Scholar
• Miyazawa S, Matsuoka S, Hamana S, Nagai S, Nakamura H, Nirei K, Moriyama M. 2015. Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection. Intern Med. 54(6):591–595.
   PubMed Web of Science ®Google Scholar
• Molla Y, Wubetu M, Dessie B. 2021. Anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients at selected hospitals, ethiopia. Hepat Med. 13:1–8.
   PubMed Web of Science ®Google Scholar
• Naidoo K, Hassan-Moosa R, Mlotshwa P, Yende-Zuma N, Govender D, Padayatchi N, Abdool-Karim SSS. 2020. High rates of drug-induced liver injury in people living with HIV coinfected with tuberculosis (TB) irrespective of antiretroviral therapy timing during antituberculosis treatment: results from the starting antiretroviral therapy at three points in TB trial. Clin Infect Dis. 70(12):2675–2682.
   PubMed Web of Science ®Google Scholar
• Naji KM, Al-Khatib BY, Al-Haj NS, D'souza MR. 2021. Hepatoprotective activity of melittin on isoniazid- and rifampicin-induced liver injuries in male albino rats. BMC Pharmacol Toxicol. 22(1):39.
   PubMed Web of Science ®Google Scholar
• Padda IS, Muralidhara Reddy K. 2022. Antitubercular medications. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557666/
   Google Scholar
• Pal R, Rana SV, Vaiphei K, Singh K. 2008. Isoniazid-rifampicin induced lipid changes in rats. Clin Chim Acta. 389(1–2):55–60.
   PubMed Web of Science ®Google Scholar
• Qu X, Zhang Y, Zhang S, Zhai J, Gao H, Tao L, Song Y. 2018. Dysregulation of BSEP and MRP2 may play an important role in isoniazid-induced liver injury via the SIRT1/FXR pathway in rats and HepG2 cells. Biol Pharm Bull. 41(8):1211–1218.
   PubMed Web of Science ®Google Scholar
• Raghu R, Karthikeyan S. 2016. Zidovudine and isoniazid induced liver toxicity and oxidative stress: Evaluation of mitigating properties of silibinin. Environ Toxicol Pharmacol. 46:217–226.
   PubMed Web of Science ®Google Scholar
• Raj Mani SS, Iyyadurai R, Mishra AK, Manjunath K, Prasad J, Lakshmanan J, Yadav B, Reginald A, Jasmine S, Hansdak SG. 2021. Predicting antitubercular drug-induced liver injury and its outcome and introducing a novel scoring system. Int J Mycobacteriol. 10(2):116–121.
   PubMed Web of Science ®Google Scholar
• Ramappa V, Aithal GP. 2013. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 3(1):37–49.
   PubMedGoogle Scholar
• Rana SV, Sharma SK, Ola RP, Kamboj JK, Malik A, Morya RK, Sinha SK. 2014. N-acetyltransferase 2, cytochrome P4502E1 and glutathione S-transferase genotypes in antitubercular treatment-induced hepatotoxicity in North Indians. J Clin Pharm Ther. 39(1):91–96.
   PubMed Web of Science ®Google Scholar
• Rawat A, Chaturvedi S, Singh AK, Guleria A, Dubey D, Keshari AK, Raj V, Rai A, Prakash A, Kumar U, et al. 2018. Metabolomics approach discriminates toxicity index of pyrazinamide and its metabolic products, pyrazinoic acid and 5-hydroxy pyrazinoic acid. Hum Exp Toxicol. 37(4):373–389.
   PubMed Web of Science ®Google Scholar
• Saad EI, El-Gowilly SM, Sherhaa MO, Bistawroos AE. 2010. Role of oxidative stress and nitric oxide in the protective effects of alpha-lipoic acid and aminoguanidine against isoniazid-rifampicin-induced hepatotoxicity in rats. Food Chem Toxicol. 48(7):1869–1875.
   PubMed Web of Science ®Google Scholar
• Sanjay S, Girish C, Toi PC, Bobby Z. 2021. Gallic acid attenuates isoniazid and rifampicin-induced liver injury by improving hepatic redox homeostasis through influence on Nrf2 and NF-κB signalling cascades in Wistar Rats. J Pharm Pharmacol. 73(4):473–486.
   PubMed Web of Science ®Google Scholar
• Santhosh S, Sini TK, Anandan R, Mathew PT. 2006. Effect of chitosan supplementation on antitubercular drugs-induced hepatotoxicity in rats. Toxicology. 219(1-3):53–59.
   PubMed Web of Science ®Google Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al. 2006. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 174(8):935–952.
   PubMed Web of Science ®Google Scholar
• Shen C, Meng Q, Zhang G, Hu W. 2008. Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures. Br J Pharmacol. 153(4):784–791.
   PubMed Web of Science ®Google Scholar
• Shih TY, Ho SC, Hsiong CH, Huang TY, Hu OY. 2013. Selected pharmaceutical excipient prevent isoniazid and rifampicin induced hepatotoxicity. Curr Drug Metab. 14(6):720–728.
   PubMed Web of Science ®Google Scholar
• Shih TY, Pai CY, Yang P, Chang WL, Wang NC, Hu OY. 2013. A novel mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob Agents Chemother. 57(4):1685–1690.
   PubMed Web of Science ®Google Scholar
• Shih TY, Young TH, Lee HS, Hsieh CB, Hu OY. 2013. Protective effects of kaempferol on isoniazid- and rifampicin-induced hepatotoxicity. Aaps J. 15(3):753–762.
   PubMed Web of Science ®Google Scholar
• Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. 2000. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 102(6):731–744.
   PubMed Web of Science ®Google Scholar
• Singla N, Gupta D, Birbian N, Singh J. 2014. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis. 94(3):293–298.
   PubMed Web of Science ®Google Scholar
• Sodhi CP, Rana SV, Mehta SK, Vaiphei K, Attari S, Mehta S. 1997. Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in young rats. Drug Chem Toxicol. 20(3):255–269.
   PubMed Web of Science ®Google Scholar
• Song Y, Qu X, Tao L, Gao H, Zhang Y, Zhai J, Gong J, Hu T. 2022. Exploration of the underlying mechanisms of isoniazid/rifampicin-induced liver injury in mice using an integrated proteomics and metabolomics approach. J Biochem Mol Toxicol. 36(12):e23217.
   PubMed Web of Science ®Google Scholar
• Su Q, Kuang W, Hao W, Liang J, Wu L, Tang C, Wang Y, Liu T. 2021. Antituberculosis drugs (rifampicin and isoniazid) induce liver injury by regulating NLRP3 inflammasomes. Mediators Inflamm. 2021:8086253.
   PubMed Web of Science ®Google Scholar
• Suh JI. 2020. Drug-induced liver injury. Yeungnam Univ J Med. 37(1):2–12.
   PubMedGoogle Scholar
• Sun C, Mao S, Chen S, Zhang W, Liu C. 2021. PPARs-orchestrated metabolic homeostasis in the adipose tissue. IJMS. 22(16):8974.
   Web of Science ®Google Scholar
• Sundaram V, Björnsson ES. 2017. Drug-induced cholestasis. Hepatol Commun. 1(8):726–735.
   PubMed Web of Science ®Google Scholar
• Tafazoli S, Mashregi M, O'Brien PJ. 2008. Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicol Appl Pharmacol. 229(1):94–101.
   PubMed Web of Science ®Google Scholar
• Tasduq SA, Kaiser P, Sharma SC, Johri RK. 2007. Potentiation of isoniazid-induced liver toxicity by rifampicin in a combinational therapy of antitubercular drugs (rifampicin, isoniazid and pyrazinamide) in Wistar rats: a toxicity profile study. Hepatol Res. 37(10):845–853.
   PubMed Web of Science ®Google Scholar
• Tasduq SA, Peerzada K, Koul S, Bhat R, Johri RK. 2005. Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin. Hepatol Res. 31(3):132–135.
   PubMed Web of Science ®Google Scholar
• Tiberi S, Scardigli A, Centis R, D'Ambrosio L, Muñoz-Torrico M, Salazar-Lezama MÁ, Spanevello A, Visca D, Zumla A, Migliori GB, et al. 2017. Classifying new anti-tuberculosis drugs: rationale and future perspectives. Int J Infect Dis. 56:181–184.
   PubMed Web of Science ®Google Scholar
• Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. 2008. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 23(2):192–202.
   PubMed Web of Science ®Google Scholar
• WHO. 2009. Treatment of tuberculosis: guidelines. 4th ed. WHO; p. 420.
   Google Scholar
• Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, et al. 2018. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med. 16(1):46.
   PubMed Web of Science ®Google Scholar
• Verma AK, Yadav A, Dewangan J, Singh SV, Mishra M, Singh PK, Rath SK. 2015. Isoniazid prevents Nrf2 translocation by inhibiting ERK1 phosphorylation and induces oxidative stress and apoptosis. Redox Biol. 6:80–92.
   PubMed Web of Science ®Google Scholar
• Verma AK, Yadav A, Singh SV, Mishra P, Rath SK. 2018. Isoniazid induces apoptosis: role of oxidative stress and inhibition of nuclear translocation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2). Life Sci. 199:23–33.
   PubMed Web of Science ®Google Scholar
• Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, Smith PJ, Carson ML, Geiter LJ. 1997. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med. 155(5):1735–1738.
   PubMed Web of Science ®Google Scholar
• Vivekanandan P, Gobianand K, Priya S, Vijayalakshmi P, Karthikeyan S. 2007. Protective effect of picroliv against hydrazine-induced hyperlipidemia and hepatic steatosis in rats. Drug Chem Toxicol. 30(3):241–252.
   PubMed Web of Science ®Google Scholar
• Wang C, Fan RQ, Zhang YX, Nie H, Li K. 2016. Naringenin protects against isoniazid- and rifampicin-induced apoptosis in hepatic injury. World J Gastroenterol. 22(44):9775–9783.
   PubMed Web of Science ®Google Scholar
• Wang J, Luo W, Li B, Lv J, Ke X, Ge D, Dong R, Wang C, Han Y, Zhang C, et al. 2018. Sagittaria sagittifolia polysaccharide protects against isoniazid- and rifampicin-induced hepatic injury via activation of nuclear factor E2-related factor 2 signaling in mice. J Ethnopharmacol. 227:237–245.
   PubMed Web of Science ®Google Scholar
• Wang P, Pradhan K, Zhong XB, Ma X. 2016. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 6(5):384–392.
   PubMed Web of Science ®Google Scholar
• Wang YC, Chen KH, Chen YL, Lin SW, Liu WD, Wang JT, Hung CC. 2022. Pyrazinamide related prolonged drug-induced liver injury: a case report. Medicine. 101(39):e30955.
   PubMed Web of Science ®Google Scholar
• Westphal JF, Vetter D, Brogard JM. 1994. Hepatic side-effects of antibiotics. J Antimicrob Chemother. 33(3):387–401.
   PubMed Web of Science ®Google Scholar
• WHO. 2022. Tuberculosis. https://www.who.int/news-room/fact-sheets/detail/tuberculosis
   Google Scholar
• Xu Y, Jiang Y, Li Y. 2020. Pyrazinamide enhances lipid peroxidation and antioxidant levels to induce liver injury in rat models through PI3k/Akt inhibition. Toxicol Res. 9(3):149–157.
   Web of Science ®Google Scholar
• Yang J, Li G, Bao X, Suo Y, Xu H, Deng Y, Feng T, Deng G. 2022. Hepatoprotective effects of phloridzin against isoniazid-rifampicin induced liver injury by regulating CYP450 and Nrf2/HO-1 pathway in mice. Chem Pharm Bull. 70(11):805–811.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Tao H, Huang C, Li J. 2013. Nuclear erythroid 2-related factor 2: a novel potential therapeutic target for liver fibrosis. Food Chem Toxicol. 59:421–427.
   PubMed Web of Science ®Google Scholar
• Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. 2005. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J. 26(3):462–464.
   PubMed Web of Science ®Google Scholar
• Zaverucha-do-Valle C, Monteiro SP, El-Jaick KB, Rosadas LA, Costa MJ, Quintana MS, de Castro L. 2014. The role of cigarette smoking and liver enzymes polymorphisms in anti-tuberculosis drug-induced hepatotoxicity in Brazilian patients. Tuberculosis. 94(3):299–305.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhu J, Zhou Y, Wei Y, Xi L, Qin H, Rao Z, Han M, Ma Y, Wu X. 2016. Hesperidin alleviates oxidative stress and upregulates the multidrug resistance protein 2 in isoniazid and rifampicin-induced liver injury in rats. J Biochem Mol Toxicol. 30(7):342–349.
   PubMed Web of Science ®Google Scholar
• Zhao H, Si ZH, Li MH, Jiang L, Fu YH, Xing YX, Hong W, Ruan LY, Li PM, Wang JS. 2017. Pyrazinamide-induced hepatotoxicity and gender differences in rats as revealed by a 1H NMR based metabolomics approach. Toxicol Res. 6(1):17–29.
   PubMed Web of Science ®Google Scholar
• Zipper LM, Mulcahy RT. 2003. Erk activation is required for Nrf2 nuclear localization during pyrrolidine dithiocarbamate induction of glutamate cysteine ligase modulatory gene expression in HepG2 cells. Toxicol Sci. 73(1):124–134.
   PubMed Web of Science ®Google Scholar